Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"

  • STATUS
    Recruiting
  • End date
    Dec 31, 2022
  • participants needed
    86
  • sponsor
    Takeda
Updated on 15 February 2021
hodgkin's disease
t-cell lymphoma
peripheral t-cell lymphoma
brentuximab vedotin
refractory lymphoma
anaplastic large cell lymphoma
large cell lymphoma
brentuximab

Summary

The purpose of this survey is to examine the safety of adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with relapsed or refractory CD30-positive PTCL or Hodgkin lymphoma (HL) in the actual use of on concomitant Brentuximab Vedotin in routine clinical practice.

Description

The drug being tested in this survey is called Brentuximab Vedotin intravenous infusion 50 mg. This intravenous infusion is being tested to treat adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with relapsed or refractory CD30-positive PTCL or Hodgkin lymphoma (HL).

This survey is an observational (non-interventional) study and will look at the safety of adult patients with relapsed or refractory CD30-positive PTCL (excluding ALCL) and pediatric patients with relapsed or refractory CD30-positive PTCL or HL in the routine clinical setting. The number of observed patients will be approximately 86 as total (80; Adult participants and 6; Pediatric participants).

This multi-center observational survey will be conducted in Japan.

Details
Condition Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Pediatric Hodgkin Lymphoma
Treatment Brentuximab vedotin (Genetical Recombination)
Clinical Study IdentifierNCT04213209
SponsorTakeda
Last Modified on15 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Gender: Male or Female
Do you have any of these conditions: T-Cell Lymphoma or Pediatric Hodgkin Lymphoma or Peripheral T-Cell Lymphoma?
Do you have any of these conditions: Peripheral T-Cell Lymphoma or Pediatric Hodgkin Lymphoma or T-Cell Lymphoma?
Do you have any of these conditions: Peripheral T-Cell Lymphoma or T-Cell Lymphoma or Pediatric Hodgkin Lymphoma?
Do you have any of these conditions: Pediatric Hodgkin Lymphoma or T-Cell Lymphoma or Peripheral T-Cell Lymphoma?
Participants with relapsed or refractory lymphoma
CD30-positive participants
Participants who receive study drug after obtaining approval of CD30-positive PTCL indication of study drug

Exclusion Criteria

Participants with a history of severe hypersensitivity to Brentuximab Vedotin
Participants taking bleomycin hydrochloride treatment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note